Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionM&t Bank Corp
Latest Disclosed Ownership13,088 shares
Latest Disclosed Value $ 5,844,316
M&t Bank Corp ownership in VRTX / Vertex Pharmaceuticals Incorporated

On May 12, 2026 - M&t Bank Corp filed a 13F-HR form disclosing ownership of 13,088 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $5,844,316 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on January 30, 2026 disclosing 14,732 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -11.16% during the quarter. The current value of the position is $5,781,493 USD.

M&t Bank Corp has a history of taking positions in derivatives of the underlying security (VRTX) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

VRTX / Vertex Pharmaceuticals Incorporated Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 13,088 -1,644 -11.16 5,844 -12.49 0.0047
2026-01-30 2025-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 14,732 2,408 19.54 6,679 38.35 0.0214
2026-01-28 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 27,610 15,286 8,422 0.0050
2025-11-14 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 12,324 -5,359 -30.31 4,827 -38.68 0.0162
2025-08-13 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 17,683 -681 -3.71 7,873 -11.58 0.0271
2025-04-30 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 18,364 -162 -0.87 8,903 19.34 0.0324
2025-02-06 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 18,526 -341 -1.81 7,461 -14.98 0.0250
2024-11-19 2024-09-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 18,867 -1,074 -5.39 8,775 -6.12 0.0289
2024-11-15 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 18,867 -1,074 8,775 0.0053
2024-07-31 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 19,941 -2,075 -9.42 9,347 1.56 0.0319
2024-05-07 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 22,016 -24,909 -53.08 9,203 -51.80 0.0320
2024-02-06 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 46,925 -4,824 -9.32 19,093 6.10 0.0701
2023-11-02 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 51,749 -2,451 -4.52 17,995 -5.65 0.0718
2023-08-09 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 54,200 1,511 2.87 19,074 14.89 0.0712
2023-05-11 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 52,689 35,703 210.19 16,601 238.52 0.0643
2023-02-13 2022-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 16,986 1,201 7.61 4,905 7.26 0.0197
2023-02-13 2022-12-31 13F VERICEL COM 92532F100 17,647 1,862 4,919 0.0198
2022-11-17 2022-09-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 15,785 1,802 12.89 4,572 23.33 0.0203
2022-11-14 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 15,785 1,802 4,152 0.0035
2022-08-05 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 13,983 2,939 26.61 3,707 28.58 0.0175
2022-05-09 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 11,044 1,901 20.79 2,883 43.58 0.0127
2022-02-07 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 9,143 65 0.72 2,008 22.07 0.0084
2021-10-28 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 9,078 -11,405 -55.68 1,645 -60.15 0.0074
2021-08-13 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 20,483 -665 -3.14 4,128 -9.17 0.0181
2021-05-06 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 21,148 -4,884 -18.76 4,545 -26.12 0.0196
2021-02-12 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 26,032 -3,403 -11.56 6,152 -23.21 0.0270
2020-11-06 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 29,435 1,630 5.86 8,011 -0.77 0.0393
2020-07-29 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 27,805 3,347 13.68 8,073 38.74 0.0433
2020-05-14 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 24,458 1,175 5.05 5,819 14.19 0.0344
2020-02-07 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 23,283 2,500 12.03 5,096 44.73 0.0239
2019-11-12 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 20,783 -4,910 -19.11 3,521 -25.28 0.0176
2019-08-12 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 25,693 792 3.18 4,712 2.88 0.0246
2019-05-15 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 24,901 -427 -1.69 4,580 9.15 0.0239
2019-02-01 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 25,328 3,619 16.67 4,196 0.29 0.0241
2018-11-09 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 21,709 850 4.07 4,184 18.06 0.0209
2018-08-10 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 20,859 596 2.94 3,544 7.33 0.0191
2018-05-04 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 20,263 -886 -4.19 3,302 4.20 0.0177
2018-02-06 2017-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 21,149 1,639 8.40 3,169 6.84 0.0166
2017-11-13 2017-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 19,510 3,748 23.78 2,966 46.04 0.0161
2017-08-11 2017-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 15,762 -564 -3.45 2,031 13.78 0.0120
2017-05-10 2017-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 16,326 -622 -3.67 1,785 43.03 0.0108
2017-02-14 2016-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 16,948 1,711 11.23 1,248 -6.09 0.0078
2016-11-04 2016-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 15,237 -176 -1.14 1,329 0.38 0.0085
2016-08-04 2016-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 15,413 -1,041 -6.33 1,324 1.22 0.0089
2016-05-11 2016-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 16,454 -5,978 -26.65 1,308 -53.67 0.0089
2016-02-12 2015-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 22,432 -1,336 -5.62 2,823 14.11 0.0187
2015-11-13 2015-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 23,768 -18,677 -44.00 2,474 -52.80 0.0169
2015-08-14 2015-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 42,445 -19,406 -31.38 5,241 -28.19 0.0316
2015-05-14 2015-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 61,851 -517 -0.83 7,298 -1.51 0.0455
2015-02-12 2014-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 62,368 17,673 39.54 7,410 47.61 0.0464
2014-11-14 2014-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 44,695 44,595 44,595.00 5,020 55,677.78 0.0352
2014-08-13 2014-06-30 13F VERTEX PHARMACEUTICALS COMMON 92532F100 100 -178 -64.03 9 -52.63 0.0004
2014-05-14 2014-03-31 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 278 -408 -59.48 19 -62.75 0.0008
2014-02-12 2013-12-31 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 686 -956 -58.22 51 -59.20 0.0021
2013-11-13 2013-09-30 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 1,642 -1,508 -47.87 125 -50.40 0.0060
2013-07-30 2013-06-30 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 3,150 3,150 252 0.0122
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2015-02-12 2014-12-31 13F VERTEX PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2014-11-14 2014-09-30 13F VERTEX PHARMACEUTICALS COM Call 200 2 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.